Type III Thyroplasty for Patients With High‐Pitched Voice Disorders: A Systematic Review and Meta‐analysis
Otolaryngology–Head and Neck Surgery · 2025-06 · 172 (6) · 1847-1855
DOI: 10.1002/ohn.1185 ↗At a glance
Systematische Übersicht in Otolaryngology–Head and Neck Surgery, published online on 2025-02-27. Written by Bruno Dalla Vecchia Vendramini and 4 co-authors. Institution: Federal University of São João del Rei, São João del Rei, Minas Gerais, Brazil. Major MEDLINE topics: Laryngoplasty, Voice Disorders. Cited 5 times so far (Crossref); 16 references.
Abstract (original language)
Objective
High‐pitched voice disorders can present notable social and professional obstacles for cisgender and transgender men. Our study aims to conduct a comprehensive meta‐analysis assessing the efficacy of type III thyroplasty, also known as relaxation thyroplasty, for different populations with high‐pitched voice disorders. Data Sources A systematic literature review was conducted following Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines, searching Medline/Pubmed, Embase, Cochrane, Science Direct, Scielo, LILACS, and Google Scholar databases from inception to April 2024. Review Methods Studies included patients undergoing type III thyroplasty for high‐pitched voice disorders. The primary outcome was the change in fundamental frequency postintervention. Subgroup analyses compared the following: (1) cisgender versus transgender populations, (2) primary versus secondary causes of high‐pitched voice disorders, and (3) unilateral versus bilateral vertical stripe resection techniques.
Results
The initial search yielded 284 articles, 9 studies, including 69 unique patients, were included in the analysis. All studies provided level 4 evidence. Most patients were cisgender men with primary mutational dysphonia (66.7%, n = 46). The meta‐analysis showed a significant reduction in fundamental frequency after surgery, with a mean difference of −75.9 Hz (95% confidence interval [CI]: −91.5 to −60.3). Cisgender men and patients submitted to unilateral resection had higher preoperative fundamental frequency and showed a more pronounced reduction in fundamental frequency. There were no significant differences between primary and secondary mutational dysphonia.
Conclusion
Type III thyroplasty effectively lowers vocal pitch in patients with high‐pitched voice disorders. The procedure is viable for both cisgender and transgender men, as well as for primary and secondary voice disorders.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Federal University of São João del Rei, São João del Rei, Minas Gerais, Brazil.
- Department of Otorhinolaryngology-Head and Neck Surgery, Federal University of Pernambuco (UFPE), Recife, Pernambuco, Brazil.
- Faculty of Medical Sciences, University of Pernambuco (UPE), Recife, Pernambuco, Brazil.
ORCID profiles: Bruno Dalla Vecchia Vendramini, Lucas Marinho Siqueira Campos, Bruno Teixeira de Moraes, Silvio José de Vasconcelos, Mateus Morais Aires
Cite
APA
Vendramini, B. D. V., Campos, L. M. S., de Moraes, B. T., de Vasconcelos, S. J., & Aires, M. M. (2025). Type III Thyroplasty for Patients With High‐Pitched Voice Disorders: A Systematic Review and Meta‐analysis. Otolaryngology–Head and Neck Surgery, 172(6), 1847-1855. https://doi.org/10.1002/ohn.1185
Vancouver
Vendramini BDV, Campos LMS, de Moraes BT, de Vasconcelos SJ, Aires MM. Type III Thyroplasty for Patients With High‐Pitched Voice Disorders: A Systematic Review and Meta‐analysis. Otolaryngology–Head and Neck Surgery. 2025;172(6):1847-1855. doi:10.1002/ohn.1185
BibTeX
@article{Vendramini2025,
author = {Vendramini, Bruno Dalla Vecchia and Campos, Lucas Marinho Siqueira and de Moraes, Bruno Teixeira and de Vasconcelos, Silvio José and Aires, Mateus Morais},
title = {Type III Thyroplasty for Patients With High‐Pitched Voice Disorders: A Systematic Review and Meta‐analysis},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2025},
volume = {172},
number = {6},
pages = {1847--1855},
doi = {10.1002/ohn.1185}
}
EUVIMED